Company / Operating Income
Lineage Cell Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$36.6M
FY2025
5-year range
-$49.2M / -$21.5M
FY2021-FY2025
Trend
-70.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$66M in FY2017 to -$21M in FY2024.
Based on SEC 10-K filings.
-$37M in FY2025.
Declined from -$25M to -$37M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 70.5% year-over-year.
- Peak operating income was recorded in FY2024.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$36.6M | -70.5% |
| FY2024 | -$21.5M | +13.2% |
| FY2023 | -$24.7M | +49.7% |
| FY2022 | -$49.2M | -86.1% |
| FY2021 | -$26.4M | +32.0% |
| FY2020 | -$38.9M | +7.0% |
| FY2019 | -$41.8M | -7.4% |
| FY2018 | -$38.9M | +40.9% |
| FY2017 | -$65.8M | -29.8% |
| FY2016 | -$50.7M | +9.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026